Novavax stock hits 52-week high at 11.99 USD
Novavax Inc. stock recently reached a 52-week high of $11.99, demonstrating a significant 31.28% increase over the past year and strong momentum in recent months. Despite this performance, InvestingPro analysis suggests the stock is currently overvalued, highlighting profitability challenges for the company. The broader biotech sector is also seeing notable activity, with Moderna and Merck reporting positive trial results for a cancer vaccine, boosting vaccine developer shares and the Nasdaq biotech index.
Novavax, Inc. (NVV1.F) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed information on Novavax, Inc. (NVV1.F) stock, including its current price, historical data, performance metrics, and key financial figures. It also offers an overview of the company's biotechnology focus, vaccine commercialization efforts, and licensing agreements. The page tracks daily and long-term stock performance against the S&P 500 benchmark.
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Novavax (NVAX) shares rose by 1.53% in a recent session, outperforming the broader market which saw declines in the S&P 500, Dow, and Nasdaq. The vaccine maker's stock has also gained 14.8% over the past month, significantly beating the Medical sector. Analysts anticipate Novavax will report earnings of -$0.37 per share, reflecting a 40.32% year-over-year growth, despite an expected 39.01% drop in quarterly revenue.
NVAX: Daily Falling Wedge Setup Eyeing $11.13 Ahead of Q3 for NASDAQ:NVAX by TaxpayerTrades
Novavax, Inc. (NVAX) is showing a bullish falling wedge pattern on its daily chart, with a potential target of $11.13. This technical setup is supported by an upcoming Q3 earnings report, which is anticipated to show the company's first profitable quarter, acting as a significant fundamental catalyst. Despite potential volatility and lower trading volume, the combination of technical indicators and a positive earnings outlook suggests a high-conviction trade opportunity, with a suggested stop-loss at $6.97.
Enterprise value to EBIT forward of Novavax, Inc. – BX:NVV1
This page on TradingView displays the enterprise value to EBIT forward for Novavax, Inc. (BX:NVV1). It appears to be a financial data point for the company on the BX Swiss exchange. The page structure includes market information, financial documents, news, community, technicals, forecasts, seasonals, ETFs, and bonds related to Novavax, Inc.
Novavax Inc. Stock Rises 4.0%, Outperforms Peers
Novavax Inc. (NVAX) saw its stock rise by 4.0%, outperforming its peers. The article, sourced from Dow Jones, notes this positive movement in the company's share price.
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Novavax (NVAX) recently closed up 1.1% at $10.11, outperforming the S&P 500 and the Medical sector, despite broader market fluctuations. The company's upcoming earnings are anticipated to show a 40.32% increase in EPS, though quarterly revenue is projected to decline. Analysts' consensus estimates for the full year suggest decreases in both EPS and revenue compared to the previous year, with Novavax currently holding a Zacks Rank of #3 (Hold).
Understanding Momentum Shifts in (NVAX)
This article analyzes Novavax Inc. (NASDAQ: NVAX), highlighting weak near-term sentiment that could precede shifts in mid and long-term outlook. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis, showing strong mid- and long-term signals despite near-term weakness.
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference
Novavax is pivoting its business model towards licensing its Matrix-M adjuvant platform, focusing on partnerships with major pharmaceutical companies for wider application, including in oncology and infectious diseases. The company has significantly reduced expenses and has a cash runway of over two years. Sanofi remains a key partner for Nuvaxovid commercialization and potential COVID-flu combination studies, contributing significantly to Novavax's financial outlook through milestones and payments.
Trading the Move, Not the Narrative: (NVAX) Edition
Novavax Inc. (NASDAQ: NVAX) shows strong sentiment across all time horizons, supporting an overweight bias. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis highlights a mid-channel oscillation pattern and an exceptional 59.3:1 risk-reward short setup.
Novavax to Participate in September Investor Conferences
Novavax, Inc. (Nasdaq: NVAX) announced its participation in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference and Citi's BioPharma Back to School Conference. Company management will hold fireside chats at both events, which will be webcast live on Novavax's investor relations website.
Gaithersburg's Novavax Sees Its Licensing Strategy Pay Off With XFG Vaccine Approvals Across Three Major Markets
Novavax's licensing strategy has proven successful with its partners Sanofi and Takeda securing approvals for the XFG-variant-adapted Nuvaxovid vaccine in the U.S., EU, and Japan. This allows Novavax to receive royalties on sales without maintaining its own commercial infrastructure. The vaccine is approved for specific populations in the U.S., aligning with a narrower eligibility criteria for updated COVID-19 vaccines since 2025.
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Novavax's partners have secured approvals for the XFG-adapted Nuvaxovid™ vaccine for the 2026-2027 vaccination season in key markets including the U.S., EU, and Japan. This allows Novavax to continue earning royalties from partner sales without direct commercial infrastructure, leveraging its protein-based, non-mRNA vaccine. The company highlights its partners' strong market positioning, particularly Takeda's success in Japan and Sanofi's expanded U.S. and international marketing efforts.
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration (FDA) has approved updated COVID vaccines from Moderna, Novavax-Sanofi, and Pfizer-BioNTech for the 2026-27 immunization season. These approvals follow an advisory panel's recommendation to target the dominant XFG variant. The manufacturers previously confirmed their capability to produce the updated shots in time for the upcoming season.
Novavax Q2 results: Revenue beats, 2026 guidance raised to $275M
Novavax (NASDAQ: NVAX) reported Q2 revenue of $56.7 million, surpassing Wall Street expectations, and raised its full-year 2026 revenue guidance to a range of $235 million-$275 million. The company's shares rose 7% following the announcement, reflecting improved operational efficiency and strong demand visibility. Novavax also highlighted its cash position of $724 million and the potential for a $125 million milestone payment from its Sanofi partnership upon the initiation of a Phase 3 COVID-19-Influenza Combination trial.
Novavax Stock Rallies Tuesday: What's Happening?
Novavax (NASDAQ: NVAX) stock is rallying due to renewed investor interest in late-stage vaccine developers, driven by positive clinical trial results from sector peers and the potential of Novavax's Matrix-M adjuvant technology. The company also reported strong second-quarter financial results, raised its full-year 2026 revenue guidance, and is progressing with a co-development partnership with Sanofi that includes a significant milestone payment. These factors, combined with cost-reduction measures, are improving Novavax's financial outlook and attracting buying interest.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) saw its stock rally 6.55% to $9.44, outperforming major indices like the NASDAQ Composite and the Dow Jones Industrial Average on a strong trading day. The company's stock closed 21.14% below its 52-week high of $11.97, which was reached on February 26th. This performance occurred as the broader market also experienced gains.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) saw its stock price rally by 6.18% to $8.94, outperforming competitors on a positive trading day for the overall stock market. The company's shares closed 25.31% below its 52-week high of $11.97. This strong performance occurred as both the NASDAQ Composite Index and the Dow Jones Industrial Average also rose.
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy Rally - Recursion Phar
Recursion Pharmaceuticals, Novavax, and CRISPR Therapeutics stocks experienced pre-market declines after a recent rally driven by positive Phase 3 results for an individualized mRNA cancer therapy from Merck & Co. and Moderna. Recursion also faced company-specific pressure from a director's plan to sell Class A shares. Despite these pre-market slips, all three stocks had closed significantly higher the previous day.
Novavax (NVAX) Is Up 10.4% After Steep Q2 Revenue Drop And Swing To Net Loss – Has The Bull Case Changed?
Novavax (NVAX) recently reported a significant Q2 2026 revenue drop to US$56.7 million from US$239.24 million and swung to a net loss of US$53.39 million. This performance puts pressure on its investment narrative, which relies on partnerships and Matrix M royalties to offset its declining COVID-dependent business. The company's future hinges on the successful execution of its deals with Sanofi, Pfizer, and Takeda, as well as the adoption of its adjuvant, with analysts projecting a fair value of $13.78, indicating a 57% upside despite the recent setbacks.
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Shares of Novavax Inc (NVAX) are trading higher due to a major clinical breakthrough in oncology by Merck & Co Inc and Moderna Inc. This success, specifically in an individualized mRNA cancer vaccine combined with Keytruda for advanced melanoma, has generated widespread positive momentum across the biotechnology sector. Novavax's proprietary Matrix-M adjuvant platform is also seen as a valuable asset, further supporting its rally.
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Novavax (NVAX) shares rose on Wednesday following a clinical breakthrough in the oncology space reported by Merck and Moderna. Their individualized mRNA cancer vaccine, combined with Keytruda, significantly improved recurrence-free survival in advanced melanoma patients, triggering a broad rally in the biopharmaceutical sector. Novavax's stock benefited from this industry-wide momentum and its own adjuvant platform, despite being known for infectious disease vaccines.
Novavax Inc. stock underperforms Tuesday when compared to competitors
Novavax Inc. (NVAX) stock fell 1.73% on Tuesday, closing at $7.93, while the broader market also experienced declines. The company's shares are currently trading 33.75% below their 52-week high of $11.97, which was reached on February 26th. This performance indicates an underperformance compared to its market competitors during the trading session.
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts
Analysts have issued a "Hold" consensus rating for Novavax (NASDAQ:NVAX), with an average 12-month price target of $13.00, significantly higher than its recent trading price of $8.05. Despite beating quarterly earnings estimates, the biopharmaceutical company reported a 76.2% year-over-year revenue decline and remains unprofitable. Institutional investors maintain significant ownership, with some firms increasing their stakes.
(NVAX) Volatility Zones as Tactical Triggers
This article analyzes Novavax Inc. (NVAX) using AI models, highlighting strong sentiment across all horizons and an exceptional 69.0:1 risk-reward setup. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to provide tactical triggers for investors.
Novavax Inc. stock underperforms Friday when compared to competitors
Novavax Inc. (NVAX) shares dropped 1.11% on Friday, closing at $8.05, despite a three-day winning streak being snapped. This underperformance occurred on a negative trading day for the broader market, with both the NASDAQ Composite and Dow Jones Industrial Average also experiencing declines.
How Novavax’s (NVAX) Earnings Slide and New Share Shelf Will Impact Investors
Novavax (NVAX) recently reported a significant decline in its second-quarter revenue and swung to a net loss, moving from profitability to a loss of US$53.39 million. The company also filed a US$82.47 million shelf registration for common shares tied to an ESOP offering. These developments raise concerns about Novavax's funding and earnings profile, potentially impacting investor perceptions and the stock's future performance.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) shares rose 2.26% to $8.14, outperforming major indices like the NASDAQ Composite and Dow Jones Industrial Average. This marked the third consecutive day of gains for the stock. The positive performance occurred during a favorable trading session for the broader market.
How Novavax’s (NVAX) Earnings Slide and New Share Shelf Will Impact Investors
Novavax (NVAX) reported a significant second-quarter revenue drop to US$56.7 million from US$239.24 million, resulting in a net loss of US$53.39 million, and filed an US$82.47 million shelf registration for new shares. This shift from profitability to loss, alongside potential share dilution, raises concerns about the company's funding and future earnings. Investors are now closely watching how these developments affect Novavax's ability to execute partner-driven milestones and manage its balance sheet.
Bank of America Corp DE Cuts Stock Holdings in Novavax, Inc. $NVAX
Bank of America Corp DE reduced its stock holdings in Novavax, Inc. (NASDAQ:NVAX) by 19.9% in the first quarter, selling over 1.65 million shares and retaining 6.64 million shares valued at approximately $54 million. Institutional investors collectively own 53.04% of the company. Analyst sentiment for Novavax is mixed, with a consensus "Hold" rating and an average price target of $13, while the company recently reported a quarterly loss despite exceeding revenue estimates.
Novavax, Inc. (NVAX) Stock Analysis: Growth Potential Amidst A 77% Upside
Novavax, Inc. (NVAX), a biotechnology company specializing in vaccines, shows a promising potential upside of 77.47% according to analyst ratings, despite current financial challenges including a 76.30% revenue decline. The company's strategic partnerships and product pipeline, including Nuvaxovid and the R21 Matrix-M malaria vaccine, position it for potential growth, though it represents a high-risk, high-reward investment due to its volatile nature and lack of immediate shareholder returns. Investors should weigh its innovative product development against its complex financial metrics and the speculative nature inherent in the biotech sector.
Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX
Renaissance Technologies LLC has acquired a new position in Novavax, Inc. (NASDAQ:NVAX), purchasing 497,383 shares valued at approximately $4.05 million. This investment represents a 0.30% stake in Novavax, which recently reported better-than-expected Q2 earnings, though revenue fell significantly year-over-year. The biopharmaceutical company has a consensus "Hold" rating from analysts, with a mixed sentiment reflected in recent upgrades and downgrades, and has raised its 2026 revenue outlook.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) stock rallied 2.71% to $7.95 on Friday, outperforming its competitors and the broader market. This marked the stock's fifth consecutive day of gains, contributing to a strong trading session where the NASDAQ Composite Index rose 1.30% and the Dow Jones Industrial Average rose 0.28%.
State Street Corporation (NYSE: STT) discloses 7.1% ownership of Novavax
State Street Corporation has disclosed a 7.1% ownership stake in Novavax, Inc., through its investment management affiliates. This beneficial ownership amounts to 11,740,566 shares of common stock. State Street holds shared voting power over 11,281,036 shares and shared dispositive power over all beneficially owned shares, with no sole voting or dispositive power.
Novavax, Inc. Stock 12‑Month Price Target Cut to $13.75, Implies 78% Upside
Novavax, Inc.'s average 12-month price target has been reduced to $13.75 from $13.88, according to 8 analysts, with forecasts ranging from $7 to $25 per share. This new target implies a potential 78% upside based on the Aug. 6 closing price. The consensus analyst rating for Novavax has shifted to "Hold," with 4 Buy, 1 Hold, and 3 Sell recommendations.
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ...
Novavax Inc. (NVAX) reported its Q2 2026 earnings, highlighting significant progress with its Matrix-M adjuvant technology through partnerships with top pharmaceutical companies, including Sanofi. The company increased its full-year 2026 revenue guidance to $235 million-$275 million, driven by strong demand for Matrix-M, and aims for non-GAAP profitability by 2028. Despite a net loss of $53 million for the quarter, largely due to the absence of one-time milestone payments, Novavax anticipates extending its cash runway into 2029.
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) reported a Q2 loss of $0.32 per share, outperforming the Zacks Consensus Estimate of a $0.36 loss, and topped revenue estimates with $56.7 million. This marks the fourth consecutive quarter the company has surpassed both EPS and revenue expectations. Despite a year-over-year decrease in revenues, Novavax shares have gained 14.6% year-to-date, and the company currently holds a Zacks Rank #1 (Strong Buy).
Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand
Novavax has increased its annual revenue forecast, driven by licensing and supply agreements for its vaccine platform rather than direct vaccine sales. The company is strategically shifting its focus to these partnerships, particularly with Sanofi, to achieve profitability by 2028, even as its second-quarter revenue saw a significant year-on-year decline. CEO John Jacobs also noted positive momentum in the U.S. regulatory environment for seasonal respiratory vaccines, following recent approvals for combination shots from competitors.
Novavax Raises 2026 Revenue Outlook After Q2 Earnings Beat
Novavax (NASDAQ: NVAX) exceeded Wall Street's Q2 earnings expectations, leading to a bump in its 2026 revenue guidance. The biotechnology company reported $57 million in revenue, driven by increased product sales despite a significant year-over-year decline due to the absence of large partner payments received in the prior year. Novavax's CEO highlighted upcoming partner milestones and progress in R&D programs.
Novavax raises 2026 outlook after Q2 beat (NVAX:NASDAQ)
Novavax (NVAX) shares rose after the company reported better-than-expected Q2 2026 financials, beating revenue estimates by $3.7 million with $57 million in revenue. Following this performance, the COVID-19 vaccine maker also raised its full-year revenue guidance.
Earnings Flash (NVAX) Novavax, Inc. Reports Q2 Revenue $56.7M, Vs. FactSet Est of $52.5M
Novavax, Inc. (NVAX) announced its Q2 revenue of $56.7 million, surpassing the FactSet estimate of $52.5 million. This earnings flash indicates the company's financial performance for the quarter, highlighting better-than-expected revenue generation.
NOVAVAX INC 2Q 2026: Revenue $56.7M, EPS ($0.32) — 10-Q Summary
NOVAVAX INC reported a significant decline in its second-quarter 2026 financial results, with revenue falling to $56.7 million and a net loss of $53.39 million, primarily due to fewer one-time milestone and agreement-related items compared to the prior year. The company's business strategy has shifted with the transfer of commercial lead for Nuvaxovid to Sanofi, impacting direct vaccine sales, while focusing on partnerships and pipeline advancements. Operational changes include ongoing restructuring, cost containment, and technology transfer milestones.
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Novavax announced its Q2 2026 financial results, reporting $57 million in total revenue and raising its full-year 2026 revenue framework to between $235 million and $275 million. The company also improved its GAAP Combined R&D and SG&A expense guidance. Key operational highlights include continued progress with the Sanofi partnership, advanced discussions with regulators for the Phase 3 COVID-19-Influenza Combination trial, and ongoing development of its C. difficile vaccine candidate.
Novavax (Nasdaq: NVAX) Q2 revenue $57M, swings to $53M loss
Novavax reported a significant financial downturn in Q2 2026, swinging to a $53 million net loss from a $107 million net income in Q2 2025, with total revenue decreasing by 76% to $57 million. This drop is primarily attributed to the absence of large milestone payments received in the prior year. Despite the revenue decline, the company raised its full-year 2026 adjusted total revenue guidance and reduced its GAAP combined R&D and SG&A expense guidance, reflecting ongoing cost-reduction efforts and its strategic partnership with Sanofi.
Novavax earnings up next: Can partnerships offset vaccine slump?
Novavax is set to report its second-quarter earnings, with investors focused on whether its new partnership strategy can compensate for declining COVID-19 vaccine sales. Analysts anticipate a significant revenue decrease and a loss per share, despite a "buy" rating from Wall Street analysts. The company is transitioning from a vaccine manufacturer to a technology licensing company, and updates on its collaborations and financial stability will be key.
Price-Driven Insight from (NVAX) for Rule-Based Strategy
This article provides a price-driven analysis for Novavax Inc. (NVAX) using AI models, outlining distinct trading strategies for various risk profiles. It highlights a positive near-term sentiment with potential mid-term weak bias within long-term strength, and identifies key support and resistance levels. The analysis also presents an exceptional risk-reward setup targeting an 18.0% gain against a 0.3% risk.
NOVAVAX INC 2Q 2026: Revenue $56.7M, EPS ($0.32) — 10-Q Summary
NOVAVAX INC (NVAX) reported a significant year-over-year decline in its second-quarter 2026 revenue and a return to a net loss, primarily due to fewer one-time milestone and agreement-related items compared to the previous year. The company's revenue dropped by 76.3% to $56.7M, with a diluted EPS of ($0.32). Despite financial setbacks, Novavax highlighted business developments including a channel shift for Nuvaxovid to Sanofi, expanded Matrix-M® collaborations, product pipeline advancements, and ongoing cost containment efforts.
Novavax Inc expected to post a loss of 39 cents a share - Earnings Preview
Novavax Inc is projected to report a loss of 39 cents per share. This earnings preview is based on information from Refinitiv. The full article can be accessed on TradingView for unlimited access to news from Reuters and other sources.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) shares rose 3.37% to $7.66 on Tuesday, outperforming competitors on a strong trading day for the stock market. This marks the second consecutive day of gains for Novavax, as both the NASDAQ Composite Index and the Dow Jones Industrial Average also saw significant increases.
Novavax Inc expected to post a loss of 39 cents a share - Earnings Preview
Novavax Inc is projected to report a loss of 39 cents per share, according to this earnings preview. The full article is available through TradingView News, which aggregates content from various sources including Reuters. This financial forecast provides a key insight into the company's expected performance.
